Ftse Mib
34.299,94
-0,22%
DAX
18.508,59
-0,49%
S&P 500
5.631,22
0,00%
NASDAQ
18.472,57
0,00%
Bitcoin
63.902,78
-1,46%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
29/10/202012:00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2020 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
27/10/202021:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
22/10/202014:00PR Newswire (US)Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020NASDAQ:BPMCBlueprint Medicines Corporation
02/10/202022:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
25/09/202017:46PR Newswire (US)Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unrese...NASDAQ:BPMCBlueprint Medicines Corporation
22/09/202014:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
22/09/202013:00PR Newswire (US)Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Pa...NASDAQ:BPMCBlueprint Medicines Corporation
20/09/202014:25PR Newswire (US)Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO...NASDAQ:BPMCBlueprint Medicines Corporation
17/09/202014:00PR Newswire (US)Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resist...NASDAQ:BPMCBlueprint Medicines Corporation
09/09/202022:01PR Newswire (US)Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
05/09/202001:00PR Newswire (US)Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion...NASDAQ:BPMCBlueprint Medicines Corporation
04/09/202022:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
01/09/202014:00PR Newswire (US)Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & DevelopmentNASDAQ:BPMCBlueprint Medicines Corporation
31/07/202022:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BPMCBlueprint Medicines Corporation
30/07/202013:00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2020 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
24/07/202014:30PR Newswire (US)Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastati...NASDAQ:BPMCBlueprint Medicines Corporation
23/07/202014:00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020NASDAQ:BPMCBlueprint Medicines Corporation
14/07/202008:08Dow Jones NewsRoche Invests in Blueprint Medicines to Develop Lung-Cancer DrugNASDAQ:BPMCBlueprint Medicines Corporation
14/07/202007:00PR Newswire (US)Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-...NASDAQ:BPMCBlueprint Medicines Corporation
01/07/202014:00PR Newswire (US)Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mut...NASDAQ:BPMCBlueprint Medicines Corporation
30/06/202000:30PR Newswire (US)Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib...NASDAQ:BPMCBlueprint Medicines Corporation
06/06/202015:00PR Newswire (US)Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Dis...NASDAQ:BPMCBlueprint Medicines Corporation
29/05/202014:00PR Newswire (US)Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Sa...NASDAQ:BPMCBlueprint Medicines Corporation
27/05/202022:30PR Newswire (US)Blueprint Medicines to Present at Upcoming Investors ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
26/05/202014:00PR Newswire (US)Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday,...NASDAQ:BPMCBlueprint Medicines Corporation
15/05/202014:00PR Newswire (US)Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Four...NASDAQ:BPMCBlueprint Medicines Corporation
14/05/202015:00PR Newswire (US)Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and System...NASDAQ:BPMCBlueprint Medicines Corporation
12/05/202018:42Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:BPMCBlueprint Medicines Corporation
06/05/202022:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BPMCBlueprint Medicines Corporation
06/05/202015:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

BIT
1GME
Gamestop
BIT
P22SO0
NLBNPIT22SO0 20241220 800
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network